Peer-influenced content. Sources you trust. No registration required. This is HCN.
GoodRx for Healthcare Professionals
If approved, retatrutide will be the first in a new class of medications combining GIP, GLP-1, and glucagon receptor agonism in a single once-weekly injection.
Endocrinology, Diabetes, Metabolism March 13th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS